|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guinney J, Wang T, Laajala TD, Winner KK,
Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, et
al: Prediction of overall survival for patients with metastatic
castration-resistant prostate cancer: Development of a prognostic
model through a crowdsourced challenge with open clinical trial
data. Lancet Oncol. 18:132–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmid S, Omlin A, Blum D, Strasser F,
Gillessen S and Rothermundt C: Assessment of anticancer-treatment
outcome in patients with metastatic castration-resistant prostate
cancer-going beyond PSA and imaging, a systematic literature
review. Ann Oncol. 26:2221–2247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
5
|
Damber JE and Aus G: Prostate cancer.
Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McCrea E, Sissung TM, Price DK, Chau CH
and Figg WD: Androgen receptor variation affects prostate cancer
progression and drug resistance. Pharmacol Res. 114:152–162. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koivisto P, Kononen J, Palmberg C, Tammela
T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A,
Visakorpi T and Kallioniemi OP: Androgen receptor gene
amplification: A possible molecular mechanism for androgen
deprivation therapy failure in prostate cancer. Cancer Res.
57:314–319. 1997.PubMed/NCBI
|
|
9
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in metastatic castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaux A, Peskoe SB, Gonzalez-Roibon N,
Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA and Netto GJ:
Loss of PTEN expression is associated with increased risk of
recurrence after prostatectomy for clinically localized prostate
cancer. Mod Pathol. 25:1543–1549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun Y, Wang BE, Leong KG, Yue P, Li L,
Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, et al: Androgen
deprivation causes epithelial-mesenchymal transition in the
prostate: Implications for androgen-deprivation therapy. Cancer
Res. 72:527–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gentleman R, Carey V, Huber W, Irizarry R
and Dudoit S: Bioinformatics and computational biology solutions
using R and Bioconductor. 746718470. Springer; New York, NY: 2005,
View Article : Google Scholar
|
|
13
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41(Database issue): D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saito R, Smoot ME, Ono K, Ruscheinski J,
Wang PL, Lotia S, Pico AR, Bader GD and Ideker T: A travel guide to
Cytoscape plugins. Nat Methods. 9:1069–1076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Assenov Y, Ramírez F, Schelhorn SE,
Lengauer T and Albrecht M: Computing topological parameters of
biological networks. Bioinformatics. 24:282–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie C, Mao X, Huang J, Ding Y, Wu J, Dong
S, Kong L, Gao G, Li CY and Wei L: KOBAS 2.0: A web server for
annotation and identification of enriched pathways and diseases.
Nucleic Acids Res. 39(Web Server issue): W316–W322. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
da W Huang, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
|
|
18
|
Maere S, Heymans K and Kuiper M: BiNGO: A
cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merseburger AS, Alcaraz A and von Klot CA:
Androgen deprivation therapy as backbone therapy in the management
of prostate cancer. Onco Targets Ther. 9:7263–7274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Penning TM, Burczynski ME, Jez JM, Hung
CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K: Human
3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the
aldo-keto reductase superfamily: Functional plasticity and tissue
distribution reveals roles in the inactivation and formation of
male and female sex hormones. Biochem J. 351:67–77. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Byrns MC, Duan L, Lee SH, Blair IA and
Penning TM: Aldo-keto reductase 1C3 expression in MCF-7 cells
reveals roles in steroid hormone and prostaglandin metabolism that
may explain its over-expression in breast cancer. J Steroid Biochem
Mol Biol. 118:177–187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Azzarello JT, Lin HK, Gherezghiher A,
Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung KM:
Expression of AKR1C3 in renal cell carcinoma, papillary urothelial
carcinoma, and Wilms' tumor. Int J Clin Exp Pathol. 3:147–155.
2009.PubMed/NCBI
|
|
23
|
Bellanger S, de Gramont A and
Sobczak-Thépot J: Cyclin B2 suppresses mitotic failure and DNA
re-replication in human somatic cells knocked down for both cyclins
B1 and B2. Oncogene. 26:7175–7184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shiota M, Itsumi M, Takeuchi A, Imada K,
Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y and
Naito S: Crosstalk between epithelial-mesenchymal transition and
castration resistance mediated by Twist1/AR signaling in prostate
cancer. Endocr Relat Cancer. 22:889–900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu JH, Wei S, Burnette PK, Gamero AM,
Hutton M and Djeu JY: Functional association of TGF-beta receptor
II with cyclin B. Oncogene. 18:269–275. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weng J, Wang J, Hu X, Wang F, Ittmann M
and Liu M: PSGR2, a novel G-protein coupled receptor, is
overexpressed in human prostate cancer. Int J Cancer.
118:1471–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kohrman AQ and Matus DQ: Divide or
conquer: Cell cycle regulation of invasive behavior. Trends Cell
Biol. 27:12–25. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vihma H, Pruunsild P and Timmusk T:
Alternative splicing and expression of human and mouse NFAT genes.
Genomics. 92:279–291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esufali S and Bapat B: Cross-talk between
Rac1 GTPase and dysregulated Wnt signaling pathway leads to
cellular redistribution of beta-catenin and TCF/LEF-mediated
transcriptional activation. Oncogene. 23:8260–8271. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang F, Li X, Sharma M, Sasaki CY, Longo
DL, Lim B and Sun Z: Linking beta-catenin to androgen-signaling
pathway. J Biol Chem. 277:11336–11344. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Coussens L, Parker PJ, Rhee L, Yang-Feng
TL, Chen E, Waterfield MD, Francke U and Ullrich A: Multiple,
distinct forms of bovine and human protein kinase C suggest
diversity in cellular signaling pathways. Science. 233:859–866.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tirado OM, Maccarthy CM, Fatima N, Villar
J, Mateo-Lozano S and Notario V: Caveolin-1 promotes resistance to
chemotherapy-induced apoptosis in Ewing's sarcoma cells by
modulating PKCalpha phosphorylation. Int J Cancer. 126:426–436.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lønne GK, Cornmark L, Zahirovic IO,
Landberg G, Jirström K and Larsson C: PKCalpha expression is a
marker for breast cancer aggressiveness. Mol Cancer. 9:762010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lichner Z, Ding Q, Samaan S, Saleh C,
Nasser A, Al-Haddad S, Samuel JN, Fleshner NE, Stephan C, Jung K
and Yousef GM: miRNAs dysregulated in association with Gleason
grade regulate extracellular matrix, cytoskeleton and androgen
receptor pathways. J Pathol. 237:226–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
